辅助生殖技术对卵巢恶性和交界性肿瘤致病风险的研究进展  

The Progress of Assisted Reproductive Technology on the Risk of Ovarian Malignant and Borderline Tumors

作　　者：王霞 朱姝 张会媛 徐炜 王秀丽 WANG Xia;ZHU Shu;ZHANG Hui-yuan;XU Wei;WANG Xiu-li(Department of Obstetrics and Gynecology,The First Medical College of Nanjing Medical University,Nanjing 210029,China;Department of Gynecology,Jiangsu Province Hospital(The First Affiliated Hospital of Nanjing Medical University),Nanjing 210036,China)

机构地区：[1]南京医科大学第一临床医学院妇产科学系,210029 [2]江苏省人民医院(南京医科大学第一附属医院)妇科

出　　处：《国际妇产科学杂志》2021年第2期148-153,共6页Journal of International Obstetrics and Gynecology

基　　金：江苏省卫生计生委科研课题(H2018017);江苏省妇幼健康重点人才课题(FRC201709)

摘　　要：辅助生殖技术(ART)的开展解决了广大不孕不育夫妇的生育难题,对人类和社会发展具有积极的作用。但ART中常用的辅助生殖药物在理论上存在着诱发女性恶性肿瘤的风险。现综合分析1990年1月—2020年6月在Pubmed、EMBASE和Cochrane Library上发表的有关ART与卵巢癌和(或)交界性卵巢肿瘤(borderline ovarian tumors,BOT)相关性的临床研究42项,系统性阐述ART及不同的辅助生殖药物对卵巢癌和BOT的致病风险。研究结果显示,多数研究(27/42,64.3%)均认为ART并不增加卵巢癌和BOT的致病风险,但也有部分研究(15/42,35.7%)认为ART存在着诱发卵巢癌或BOT的潜在风险,尤其是近5年的研究(6/10,60%)对此结论多呈肯定态度。对于ART与卵巢癌和BOT之间的相关性,还需要长期、大样本的研究进行随访和评估。The development of assisted reproductive technology(ART)solves the fertility problems of infertile couples,and has a positive effect on human and social progress.However,the medicines commonly used in ART,such as ovary stimulation drugs or progestins,theoretically have the potential risk of inducing female malignant tumors.This article comprehensively reviews 42 clinical studies on the correlation between ART and malignant and/or borderline ovarian tumors reported in English from January 1990 to June 2020,systematically elaborates the risk of ART and fertility drugs on ovary cancer and borderline ovarian tumors.Most of these studies(27/42,64.3%)showed that ART does not increase the risk of ovary cancer and BOT,but there are also some studies(15/42,35.7%)affirmed the potential risk of ART on ovary cancer or BOT,especially the researches in the recent 5 years(6/10,60.0%).The correlation between ART and ovary cancer and BOT need long-term,large sample follow-up and evaluation.

关 键 词：生殖技术 辅助 卵巢肿瘤 交界性卵巢肿瘤 促性腺素释放激素 促性腺素类 

分 类 号：R737.31[医药卫生—肿瘤] R714.8[医药卫生—临床医学]